Please login to the form below

Not currently logged in
Email:
Password:

trebananib

This page shows the latest trebananib news and features for those working in and with pharma, biotech and healthcare.

Takeda hands back rights to two Amgen drugs

Takeda hands back rights to two Amgen drugs

However, Takeda has decided it is no longer interested in developing pain candidate fulranumab (AMG403) and trebananib (AMG386), which is being tested in cancer. ... In the case of trebananib the picture seems clearer - the compound has already failed

Latest news

  • Amgen's trebananib misses survival target in ovarian cancer Amgen's trebananib misses survival target in ovarian cancer

    tumours. In the phase III study - called TRINOVA-1 - trebananib plus paclitaxel was compared to paclitaxel alone in women with recurrent platinum-resistant ovarian cancer. ... he described the overall survival data from TRINOVA-1 as a "binary event" for

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Trebananib appears to be closer than nintedanib to approval, given that the primary endpoint (PFS) was achieved in the phase III TRINOVA-1 trial. ... In this trial, 919 patients with recurrent ovarian, primary peritoneal or fallopian tube cancers were

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics